The Curious Case Of The Ranbaxy-Teva Lipitor Deal; NY AG Reveals Hidden Provision
This article was originally published in The Pink Sheet Daily
The New York Attorney General obtains a $300,000 settlement with Ranbaxy and Teva for their agreement not to challenge each other’s market exclusivity rights; the arrangement was part of a deal that gave Teva a cut of Ranbaxy’s atorvastatin sales.
You may also be interested in...
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
Infographic timeline looks at key moments in the history of vaccine development, from the first vaccine against smallpox to the polio field trial involving 1.8 million children to the flurry of vaccines created by ‘the scientist who saved more lives than all other scientists combined.’
Members of House Energy & Commerce Committee reiterate concerns that 2001 label revision may have been used to help promote higher dosage and longer-term prescriptions of OxyContin. J&J boosts opioid litigation settlement offer to $5bn.